Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the single-dose relative bioavailability of
Ranbaxy and Schering (Claritin-D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate
Extended-Release Tablets, in a fully replicated design, under fed conditions.